Abbott Laboratories 1ABT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
This test screens for 50 cancers - but whether Medicare and other health insurers will cover it hinges on FDA approval
-
Abbott to Pay $385 Million to Resolve Baby Formula Contamination Claims
-
Abbott Receives FDA Approval for Device to Treat Abnormal Heart Rhythm
-
Abbott to Pay $670 Million to Settle Baby-Formula Litigation
-
Abbott Laboratories Up Over 11%, on Pace for Largest Percent Increase Since July 2002 — Data Talk
-
Abbott Laboratories 2Q Sales Rise on Diagnostics Growth
-
A new blood test can help detect colon cancer, but it's not as good as the test you hate to take
-
Abbott Laboratories on Pace for Largest Percent Increase Since April 2023 — Data Talk
Trading Information
- Previous Close Price
- €87.46
- Day Range
- €88.10–88.10
- 52-Week Range
- €70.20–116.10
- Bid/Ask
- €0.00 / €0.00
- Shares Outstanding
- 1.73B
- Market Cap
- $153.97B
- Volume/Avg
- 18 / 276
Key Statistics
- Price/Earnings (Normalized)
- 19.27
- Price/Sales
- 3.80
- Dividend Yield (Trailing)
- 2.44%
- Dividend Yield (Forward)
- 2.59%
- Dividend Payment Schedule
- Feb, May, Aug, Nov
- Total Yield
- 3.46%
Company Profile
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Large Value
- Total Number of Employees
- 115,000
- Website
- https://www.abbott.com
Competitors
Valuation
|
Metric
|
1ABT
|
MDT
|
RHHBY
|
|---|---|---|---|
Price/Earnings (Normalized) | 19.27 | 15.63 | 19.13 |
Price/Book Value | 3.36 | 2.25 | 8.52 |
Price/Sales | 3.80 | 3.03 | 4.39 |
Price/Cash Flow | 16.20 | 12.70 | 13.75 |
Price/Earnings
1ABT
MDT
RHHBY
Financial Strength
|
Metric
|
1ABT
|
MDT
|
RHHBY
|
|---|---|---|---|
Quick Ratio | 0.97 | 1.29 | 0.80 |
Current Ratio | 1.38 | 2.07 | 1.23 |
Interest Coverage | 10.40 | 10.12 | 13.49 |
Quick Ratio
1ABT
MDT
RHHBY
Profitability
|
Metric
|
1ABT
|
MDT
|
RHHBY
|
|---|---|---|---|
Return on Assets (Normalized) | 9.71% | 8.31% | 15.81% |
Return on Equity (Normalized) | 17.95% | 15.59% | 48.77% |
Return on Invested Capital (Normalized) | 13.03% | 10.57% | 23.90% |
Return on Assets
1ABT
MDT
RHHBY
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|?><<><$ | LOCK|?#y>^ | $172B | |||
| Medtronic PLC
MDT
| LOCK|XkbnPn& | LOCK|%yLsM | $113B | |||
| Stryker Corp
SYK
| LOCK|?T>?!$R | LOCK|^XP | $106B | |||
| Boston Scientific Corp
BSX
| LOCK|mkq<&n> | LOCK|!?!s^ | $62B | |||
| Edwards Lifesciences Corp
EW
| LOCK|zrpm^M%@ | LOCK|$k?$Q | $49B | |||
| DexCom Inc
DXCM
| LOCK|<?R&drb | LOCK|Y>@HT | $32B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|Vcm<cgl | LOCK|Bw | $30B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|rtK | LOCK|gzZ | $24B | |||
| Steris PLC
STE
| LOCK|<lJjzw | LOCK|%gp!$ | $21B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|#@mzcq#Z | LOCK|fjd | $17B |
United States